Seven numbers in the abstract
Where each one falls
Where it lands on the map
the abstract, start to end
… death [6 studies, 24,410 patients, OR:0.65, 95%CI: 0.53-0.80], all malignancies [18 studies, 561,836 patients, OR:0.73, 95%CI: 0.61-0.88], liver [8 studies, 312,742 patients, OR:0.34; 95%CI: 0.19-0.60] colorectal [12 studies, 871,365 patients, OR:0.83, 95%CI: 0.74-0.92], pancreas [9 studies, 847,248 patients, OR:0.56, 95%CI: 0.36-0.86], stomach [2 studies, 100701 patients, OR:0.83, 95%CI: 0.76-0.91], and esophagus cancer [2 studies, 100694 patients, OR:0.90, 95%CI: 0.83-0.98].
← favours treatmentfavours comparator →
could be chancePharmacokinetics & dosing
OR 0.650.53–0.80
Adverse events & safety
OR 0.730.61–0.88
Adverse events & safety
OR 0.340.19–0.60
Adverse events & safety
OR 0.830.74–0.92
Adverse events & safety
OR 0.830.76–0.91
Adverse events & safety
OR 0.560.36–0.86
Adverse events & safety
OR 0.900.83–0.98
MetforminAdverse events & safetyPharmacokinetics & dosing
1 / 3